Search

for
Search:

Research

5 / 1000+ results

research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol

4 citations , September 2024 in “BMC Cancer”

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

research LB1671 Large-scale skin scRNA-seq profiling highlights distinct body site-specific ligand-receptor interactions and pathways in keratinocytes

August 2023 in “Journal of Investigative Dermatology”

This study using scRNA-seq on 96 skin biopsies from 51 healthy individuals revealed distinct cell signaling pathways in different skin sites, including unique pathways in facial and palmoplantar skin, which may explain their varying susceptibilities to skin disorders.

research Complex Changes in the Apoptotic and Cell Differentiation Programs during Initiation of the Hair Follicle Response to Chemotherapy

12 citations , July 2014 in “Journal of Investigative Dermatology”

This study found that doxorubicin induces hair follicle apoptosis through TRAIL receptor signaling, providing insights for managing chemotherapy-induced hair loss.

research Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation

July 2026 in “Pharmacological Reports”

In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.

research c-Kit - The Novel Receptor: Physiological Roles, Downstream Signaling and Implications in Cancer

4 citations , January 2021 in “Journal of Clinical Medical Research”

This review provides an in-depth analysis of the structure and function of c-kit activation, and its role in both normal physiological and pathological conditions, with no new research findings reported.

View more "trail receptor signaling" in research →

Community Join

5 / 1000+ results

community Is there a topical androgen receptor blocker so we don't have to fuck with the enzyme and destroy our allopregnanolone, but go and hit the end target straight?

in Treatment 44 upvotes 2 years ago

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

90 upvotes 3 years ago

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

community Korean scientists breakthrough in hair regeneration targeting CXXC5 protein and WNT Signaling Pathway

53 upvotes 8 years ago

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

124 upvotes 2 years ago

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

community Why Fin/Dut Isn't Working for You GPR133: a new hairloss mechanism + Steroid Hair Loss Deep Dive

6 upvotes 2 months ago

Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.

View more "trail receptor signaling" in community →

Learn

8 / 800 results

learn HMI-115

much-hyped research compound targeting prolactin receptor in scalp

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn Neem Oil

natural substance from Neem tree with medicinal and pesticidal properties

learn Bicalutamide

Can bicalutamide stop DHT from shrinking your hair follicles? Bicalutamide blocks androgens at the receptor rather than lowering DHT, and some dermatologists prescribe it off-label for women with pattern hair loss. The published evidence is retrospective case series and one small pilot study, with no randomized trial; it is a prescription drug that requires liver monitoring and is contraindicated in pregnancy.

learn Fluridil

How is Fluridil different from other DHT blockers like finasteride? Fluridil is a topical androgen-receptor blocker applied to the scalp, while finasteride is an oral 5-alpha-reductase inhibitor that lowers DHT throughout the body. Finasteride is FDA-approved and far better studied; Fluridil rests on one 43-man trial and is not licensed as a hair-loss medicine, so its long-term safety and effect size are unknown.

learn Setipiprant

What is Setipiprant and how does it differ from DHT blockers like finasteride or dutasteride? Setipiprant blocks the prostaglandin D2 receptor DP2 rather than the DHT pathway that finasteride and dutasteride act on. The one published human trial — a 169-man, 24-week phase 2a study at 2,000 mg a day — reported no statistically significant improvement in hair density over placebo, and setipiprant is not an approved hair-loss medicine anywhere.
How does Setipiprant work on the scalp to potentially promote hair regrowth? Setipiprant blocks the DP2 (CRTH2) receptor that prostaglandin D₂ acts through, and PGD₂ is reported to be elevated in balding scalp — but the one published placebo-controlled trial in men (DuBois 2021, n=169) found no significant hair regrowth. It is an experimental compound, not an approved hair-loss medicine.

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

learn GT20029

research compound made to degrade androgen receptors in scalp

View more "trail receptor signaling" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →